984 related articles for article (PubMed ID: 30146931)
1. Effects of Aspirin for Primary Prevention in Persons with Diabetes Mellitus.
; Bowman L; Mafham M; Wallendszus K; Stevens W; Buck G; Barton J; Murphy K; Aung T; Haynes R; Cox J; Murawska A; Young A; Lay M; Chen F; Sammons E; Waters E; Adler A; Bodansky J; Farmer A; McPherson R; Neil A; Simpson D; Peto R; Baigent C; Collins R; Parish S; Armitage J
N Engl J Med; 2018 Oct; 379(16):1529-1539. PubMed ID: 30146931
[TBL] [Abstract][Full Text] [Related]
2. Effects of n-3 Fatty Acid Supplements in Diabetes Mellitus.
; Bowman L; Mafham M; Wallendszus K; Stevens W; Buck G; Barton J; Murphy K; Aung T; Haynes R; Cox J; Murawska A; Young A; Lay M; Chen F; Sammons E; Waters E; Adler A; Bodansky J; Farmer A; McPherson R; Neil A; Simpson D; Peto R; Baigent C; Collins R; Parish S; Armitage J
N Engl J Med; 2018 Oct; 379(16):1540-1550. PubMed ID: 30146932
[TBL] [Abstract][Full Text] [Related]
3. Ticagrelor in Patients with Stable Coronary Disease and Diabetes.
Steg PG; Bhatt DL; Simon T; Fox K; Mehta SR; Harrington RA; Held C; Andersson M; Himmelmann A; Ridderstråle W; Leonsson-Zachrisson M; Liu Y; Opolski G; Zateyshchikov D; Ge J; Nicolau JC; Corbalán R; Cornel JH; Widimský P; Leiter LA;
N Engl J Med; 2019 Oct; 381(14):1309-1320. PubMed ID: 31475798
[TBL] [Abstract][Full Text] [Related]
4. Association of Aspirin Use for Primary Prevention With Cardiovascular Events and Bleeding Events: A Systematic Review and Meta-analysis.
Zheng SL; Roddick AJ
JAMA; 2019 Jan; 321(3):277-287. PubMed ID: 30667501
[TBL] [Abstract][Full Text] [Related]
5. Low-Dose Aspirin for Primary Prevention of Cardiovascular Events in Elderly Japanese Patients with Atherosclerotic Risk Factors: Subanalysis of a Randomized Clinical Trial (JPPP-70).
Sugawara M; Goto Y; Yamazaki T; Teramoto T; Oikawa S; Shimada K; Uchiyama S; Ando K; Ishizuka N; Murata M; Yokoyama K; Uemura Y; Ikeda Y;
Am J Cardiovasc Drugs; 2019 Jun; 19(3):299-311. PubMed ID: 30565155
[TBL] [Abstract][Full Text] [Related]
6. Rivaroxaban in Peripheral Artery Disease after Revascularization.
Bonaca MP; Bauersachs RM; Anand SS; Debus ES; Nehler MR; Patel MR; Fanelli F; Capell WH; Diao L; Jaeger N; Hess CN; Pap AF; Kittelson JM; Gudz I; Mátyás L; Krievins DK; Diaz R; Brodmann M; Muehlhofer E; Haskell LP; Berkowitz SD; Hiatt WR
N Engl J Med; 2020 May; 382(21):1994-2004. PubMed ID: 32222135
[TBL] [Abstract][Full Text] [Related]
7. Effect of Aspirin on Cardiovascular Events and Bleeding in the Healthy Elderly.
McNeil JJ; Wolfe R; Woods RL; Tonkin AM; Donnan GA; Nelson MR; Reid CM; Lockery JE; Kirpach B; Storey E; Shah RC; Williamson JD; Margolis KL; Ernst ME; Abhayaratna WP; Stocks N; Fitzgerald SM; Orchard SG; Trevaks RE; Beilin LJ; Johnston CI; Ryan J; Radziszewska B; Jelinek M; Malik M; Eaton CB; Brauer D; Cloud G; Wood EM; Mahady SE; Satterfield S; Grimm R; Murray AM;
N Engl J Med; 2018 Oct; 379(16):1509-1518. PubMed ID: 30221597
[TBL] [Abstract][Full Text] [Related]
8. Low-dose aspirin for primary prevention of cardiovascular events in Japanese patients 60 years or older with atherosclerotic risk factors: a randomized clinical trial.
Ikeda Y; Shimada K; Teramoto T; Uchiyama S; Yamazaki T; Oikawa S; Sugawara M; Ando K; Murata M; Yokoyama K; Ishizuka N
JAMA; 2014 Dec; 312(23):2510-20. PubMed ID: 25401325
[TBL] [Abstract][Full Text] [Related]
9. Age-specific risks, severity, time course, and outcome of bleeding on long-term antiplatelet treatment after vascular events: a population-based cohort study.
Li L; Geraghty OC; Mehta Z; Rothwell PM;
Lancet; 2017 Jul; 390(10093):490-499. PubMed ID: 28622955
[TBL] [Abstract][Full Text] [Related]
10. Role of Aspirin for Primary Prevention in Persons with Diabetes Mellitus and in the Elderly.
Patel NJ; Baliga RR
Curr Cardiol Rep; 2020 May; 22(7):48. PubMed ID: 32472363
[TBL] [Abstract][Full Text] [Related]
11. Aspirin with or without Clopidogrel after Transcatheter Aortic-Valve Implantation.
Brouwer J; Nijenhuis VJ; Delewi R; Hermanides RS; Holvoet W; Dubois CLF; Frambach P; De Bruyne B; van Houwelingen GK; Van Der Heyden JAS; Toušek P; van der Kley F; Buysschaert I; Schotborgh CE; Ferdinande B; van der Harst P; Roosen J; Peper J; Thielen FWF; Veenstra L; Chan Pin Yin DRPP; Swaans MJ; Rensing BJWM; van 't Hof AWJ; Timmers L; Kelder JC; Stella PR; Baan J; Ten Berg JM
N Engl J Med; 2020 Oct; 383(15):1447-1457. PubMed ID: 32865376
[TBL] [Abstract][Full Text] [Related]
12. Update on aspirin in the treatment and prevention of cardiovascular disease.
Hennekens CH
Am J Manag Care; 2002 Dec; 8(22 Suppl):S691-700. PubMed ID: 12512736
[TBL] [Abstract][Full Text] [Related]
13. A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women.
Ridker PM; Cook NR; Lee IM; Gordon D; Gaziano JM; Manson JE; Hennekens CH; Buring JE
N Engl J Med; 2005 Mar; 352(13):1293-304. PubMed ID: 15753114
[TBL] [Abstract][Full Text] [Related]
14. Aspirin to target arterial events in chronic kidney disease (ATTACK): study protocol for a multicentre, prospective, randomised, open-label, blinded endpoint, parallel group trial of low-dose aspirin vs. standard care for the primary prevention of cardiovascular disease in people with chronic kidney disease.
Gallagher H; Dumbleton J; Maishman T; Whitehead A; Moore MV; Fuat A; Fitzmaurice D; Henderson RA; Lord J; Griffith KE; Stevens P; Taal MW; Stevenson D; Fraser SD; Lown M; Hawkey CJ; Roderick PJ
Trials; 2022 Apr; 23(1):331. PubMed ID: 35449015
[TBL] [Abstract][Full Text] [Related]
15. Dual antiplatelet therapy using cilostazol for secondary prevention in patients with high-risk ischaemic stroke in Japan: a multicentre, open-label, randomised controlled trial.
Toyoda K; Uchiyama S; Yamaguchi T; Easton JD; Kimura K; Hoshino H; Sakai N; Okada Y; Tanaka K; Origasa H; Naritomi H; Houkin K; Yamaguchi K; Isobe M; Minematsu K;
Lancet Neurol; 2019 Jun; 18(6):539-548. PubMed ID: 31122494
[TBL] [Abstract][Full Text] [Related]
16. Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease.
Eikelboom JW; Connolly SJ; Bosch J; Dagenais GR; Hart RG; Shestakovska O; Diaz R; Alings M; Lonn EM; Anand SS; Widimsky P; Hori M; Avezum A; Piegas LS; Branch KRH; Probstfield J; Bhatt DL; Zhu J; Liang Y; Maggioni AP; Lopez-Jaramillo P; O'Donnell M; Kakkar AK; Fox KAA; Parkhomenko AN; Ertl G; Störk S; Keltai M; Ryden L; Pogosova N; Dans AL; Lanas F; Commerford PJ; Torp-Pedersen C; Guzik TJ; Verhamme PB; Vinereanu D; Kim JH; Tonkin AM; Lewis BS; Felix C; Yusoff K; Steg PG; Metsarinne KP; Cook Bruns N; Misselwitz F; Chen E; Leong D; Yusuf S;
N Engl J Med; 2017 Oct; 377(14):1319-1330. PubMed ID: 28844192
[TBL] [Abstract][Full Text] [Related]
17. Aspirin for primary prevention of coronary heart disease: safety and absolute benefit related to coronary risk derived from meta-analysis of randomised trials.
Sanmuganathan PS; Ghahramani P; Jackson PR; Wallis EJ; Ramsay LE
Heart; 2001 Mar; 85(3):265-71. PubMed ID: 11179262
[TBL] [Abstract][Full Text] [Related]
18. Use of aspirin to reduce risk of initial vascular events in patients at moderate risk of cardiovascular disease (ARRIVE): a randomised, double-blind, placebo-controlled trial.
Gaziano JM; Brotons C; Coppolecchia R; Cricelli C; Darius H; Gorelick PB; Howard G; Pearson TA; Rothwell PM; Ruilope LM; Tendera M; Tognoni G;
Lancet; 2018 Sep; 392(10152):1036-1046. PubMed ID: 30158069
[TBL] [Abstract][Full Text] [Related]
19. Low-dose aspirin for primary prevention of cardiovascular events in patients with diabetes: a meta-analysis.
Stavrakis S; Stoner JA; Azar M; Wayangankar S; Thadani U
Am J Med Sci; 2011 Jan; 341(1):1-9. PubMed ID: 21191260
[TBL] [Abstract][Full Text] [Related]
20. Low-Dose Aspirin for Primary Prevention of Cardiovascular Events in Patients With Type 2 Diabetes Mellitus: 10-Year Follow-Up of a Randomized Controlled Trial.
Saito Y; Okada S; Ogawa H; Soejima H; Sakuma M; Nakayama M; Doi N; Jinnouchi H; Waki M; Masuda I; Morimoto T;
Circulation; 2017 Feb; 135(7):659-670. PubMed ID: 27881565
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
